London: BridgeBio Pharma said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland.
The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to warrant additional capital investment.
It will reduce its gene therapy development budget by more than $50 million, and seek partnership opportunities to support future development of the therapy, BBP-631, or newer treatments for congenital adrenal hyperplasia (CAH).
CAH is a group of genetic disorders caused by a mutation in an enzyme needed to produce cortisol, which is secreted by the adrenal gland.
The study showed that higher doses of BBP-631 increased production of cortisol in all patients.
Cortisol helps the body to respond to injury, stress or illness.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)
Be the first one to comment.
Comment Now
COMMENTS
Comment Now
Read Comment (1)
All Comments
By commenting, you agree to the Prohibited Content Policy
Post
By commenting, you agree to the Prohibited Content Policy
Post
Find this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions
REASONS FOR REPORTING